Funding Opportunities

NIH Funding Opportunities

Notice of Change to Application Instructions in PAR-14-041 "Center for AIDS Research and Developmental Center for AIDS Research (P30)"
Notice NOT-AI-14-063 from the NIH Guide for Grants and Contracts
Tue, 22 Jul 2014 03:34:42 EST

Mucosal Environment and HIV Prevention (MEHP II) (R01)
Funding Opportunity RFA-AI-14-036 from the NIH Guide for Grants and Contracts. The purpose of the Mucosal Environment and HIV Prevention II (MEHP II) Funding Opportunity Announcement (FOA) is to solicit applications that support innovative proof-of-concept/feasibility non-vaccine biomedical prevention (nBP) research needed to support and advance the development of safer and more effective microbicides and Pre-Exposure Prophylaxis (PrEP) strategies. The MEHP II will support innovative, high-risk, hypothesis-driven research that provides a better understanding of how prevention products/drug delivery strategies interact with the micro- and macro-environments of the male and female genital and gastrointestinal (GI) mucosa. This FOA is intended to support innovative biomedical research efforts, which may or may not involve active pharmaceutical ingredients (APIs), formulation/excipient and/or a device currently under development. This FOA is not intended to support the preclinical or clinical development of new nBP candidates or their delivery systems.
Tue, 22 Jul 2014 10:08:08 EST

Interventions for Youth who Misuse/Abuse Prescription Stimulant Medications in High School and/or College-Attending Youth (U01)
Funding Opportunity RFA-DA-15-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits U01 applications conducting either hypothesis-driven or hypothesis-generating controlled research to build an evidence base to address the problem of prescription stimulant medication (PSM) misuse in youth. Specifically this FOA solicits research applications that develop and test the efficacy of interventions to either prevent or reduce the misuse and diversion of PSMs among high school students and/or college students. Animal studies and epidemiological research will be considered unresponsive.
Tue, 22 Jul 2014 02:55:32 EST

Advanced Clinical Trials to test Artificial Pancreas Device Systems in Type 1 Diabetes (UC4)
Funding Opportunity RFA-DK-14-024 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control and reducing acute and chronic complications of the disease. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems.
Tue, 22 Jul 2014 01:07:26 EST

National Research Project to Assess State Agricultural Laws, Regulations, and Resources Related to Produce Safety (U01)
Funding Opportunity RFA-FD-14-085 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is issued to announce the availability of a Cooperative Agreement to be awarded under a Limited Competition. The goal of this Cooperative Agreement is to facilitate long term improvements to the national food safety system by providing States with information to help identify needed changes and resources to enforce produce safety requirements modeled after FDAs produce safety rule. The information also would assist FDA in implementing the produce safety rule.
Tue, 22 Jul 2014 02:13:22 EST

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44)
Funding Opportunity PAR-14-292 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.
Tue, 22 Jul 2014 03:14:31 EST

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3)
Funding Opportunity PAR-14-293 from the NIH Guide for Grants and Contracts. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.
Tue, 22 Jul 2014 03:14:09 EST